1 |
dpavlin |
1.1 |
<table width="100%" border="0" cellspacing="2"> |
2 |
|
|
<tr> |
3 |
|
|
<td> |
4 |
|
|
<p><img src="p/110.jpg" width="150" height="95" align="left" vspace="5" hspace="3" border="1"><font size="2" face="Arial, Helvetica, sans-serif" color="#000080">This |
5 |
|
|
year's Organic Chemistry Award Vladimir |
6 |
|
|
Prelog was presented to Valerije Vrcek, |
7 |
|
|
Ph.D., a young scientist from the Faculty |
8 |
|
|
of Pharmacy and Biochemistry in Zagreb for |
9 |
|
|
his exceptional contribution to synthesis |
10 |
|
|
of nucleosides, understanding of carbocationic |
11 |
|
|
rearrangements and NMR spectroscopy of organic |
12 |
|
|
molecules. The Vladimir Prelog Organic Chemistry |
13 |
|
|
Award was established in 1996 as a means |
14 |
|
|
of encouragement for young Croatian scientists |
15 |
|
|
in the field of organic chemistry. It was |
16 |
|
|
founded by PLIVA and the Croatian Chemical |
17 |
|
|
Society to mark 90 years of the birth of |
18 |
|
|
Vladimir Prelog, the renowned Croatian scientist |
19 |
|
|
and Nobel Prize Winner.This year's Organic |
20 |
|
|
Chemistry Award Vladimir</font></p> |
21 |
|
|
<p><font size="2" face="Arial, Helvetica, sans-serif" color="#000080"> |
22 |
|
|
Prelog was presented to Valerije Vrcek, |
23 |
|
|
Ph.D., a young scientist from the Faculty |
24 |
|
|
of Pharmacy and Biochemistry in Zagreb for |
25 |
|
|
his exceptional contribution to synthesis |
26 |
|
|
of nucleosides, understanding of carbocationic |
27 |
|
|
rearrangements and NMR spectroscopy of organic |
28 |
|
|
molecules. The Vladimir Prelog Organic Chemistry |
29 |
|
|
Award was established in 1996</font><font size="2" face="Verdana, Arial, Helvetica, sans-serif" color="#000080"> |
30 |
|
|
</font></p> |
31 |
|
|
</td> |
32 |
|
|
</tr> |
33 |
|
|
<tr> |
34 |
|
|
<td height="2"> |
35 |
|
|
<hr size="1" width="100%"> |
36 |
|
|
</td> |
37 |
|
|
</tr> |
38 |
|
|
<tr valign="top"> |
39 |
|
|
<td> |
40 |
|
|
<p align=justify><img height=100 hspace=3 |
41 |
|
|
src="p/str1.gif" width=150 align=left border=1 vspace="5"><font face="Arial, Helvetica, sans-serif" color="#000080" size="2">Research |
42 |
|
|
and Development is central to both PLIVA's |
43 |
|
|
past and future success. For that reason, |
44 |
|
|
PLIVA pays careful attention to the organization |
45 |
|
|
of R&D activities, ensuring that research |
46 |
|
|
and development activities are closely aligned |
47 |
|
|
to the company's core business.<br> |
48 |
|
|
<br> |
49 |
|
|
The prime goal of research at PLIVA is the |
50 |
|
|
development of new chemical entities which |
51 |
|
|
can be developed into innovative medicines |
52 |
|
|
to combat illness and improve the quality |
53 |
|
|
of life for people around the world. Our |
54 |
|
|
researchers, assistants and lab technicians |
55 |
|
|
as well as all employees at PLIVA understand |
56 |
|
|
that our primary task is helping people.</font> |
57 |
|
|
<p align=justify><font face="Arial, Helvetica, sans-serif" color="#000080" size="2">PLIVA's |
58 |
|
|
blockbuster antibiotic <b>azithromycin</b> |
59 |
|
|
is a good example of how the dedication |
60 |
|
|
of the PLIVA's R&D staff brought about |
61 |
|
|
the discovery and development of a medicine |
62 |
|
|
which is now fighting disease worldwide, |
63 |
|
|
sold as <b>Sumamed</b> by PLIVA and licensed |
64 |
|
|
to Pfizer which markets it as <b>Zithromax</b>. |
65 |
|
|
At this very moment, the staff of PLIVA's |
66 |
|
|
research institute are working on new, innovative |
67 |
|
|
and original medicines which will carry |
68 |
|
|
on PLIVA's battle against disease.</font> |
69 |
|
|
</td> |
70 |
|
|
</tr> |
71 |
|
|
<tr> |
72 |
|
|
<td height="2"> |
73 |
|
|
<hr size="1" width="100%"> |
74 |
|
|
</td> |
75 |
|
|
</tr> |
76 |
|
|
<tr valign="top"> |
77 |
|
|
<td> |
78 |
|
|
<table cellspacing=0 cellpadding=0 width=360 border=0> |
79 |
|
|
<tbody> |
80 |
|
|
<tr> |
81 |
|
|
<td width=70 height="66"><img height=90 |
82 |
|
|
src="p/portret_spaventi.gif" width=70 border=0></td> |
83 |
|
|
<td width=15 height="66"></td> |
84 |
|
|
<td valign=top align=left width=275 height="66"><br> |
85 |
|
|
<font face=Arial color=#000080 size=1>RADAN |
86 |
|
|
SPAVENTI, M.D., Ph.D.<br> |
87 |
|
|
Research & Development, Direcor<br> |
88 |
|
|
Management Board, Vice President for |
89 |
|
|
R&D<br> |
90 |
|
|
Phone: 3851/3781 078<br> |
91 |
|
|
Fax: 3851/370 3175<br> |
92 |
|
|
E-mail: <a |
93 |
|
|
href="mailto:radan.spaventi@pliva.hr">radan.spaventi@pliva.hr</a><br> |
94 |
|
|
</font> </td> |
95 |
|
|
</tr> |
96 |
|
|
</tbody> |
97 |
|
|
</table> |
98 |
|
|
</td> |
99 |
|
|
</tr> |
100 |
|
|
<tr> |
101 |
|
|
<td height="2"> |
102 |
|
|
<hr size="1" width="100%"> |
103 |
|
|
</td> |
104 |
|
|
</tr> |
105 |
|
|
<tr> |
106 |
|
|
<td> |
107 |
|
|
<table cellspacing=0 cellpadding=0 width=360 border=0> |
108 |
|
|
<tbody> |
109 |
|
|
<tr> |
110 |
|
|
<td width=70 height="86"><img height=81 |
111 |
|
|
src="p/portret_kovacevic.gif" width=70 |
112 |
|
|
border=0></td> |
113 |
|
|
<td width=15 height="86"></td> |
114 |
|
|
<td valign=top align=left width=275 height="86"><br> |
115 |
|
|
<font face=Arial color=#000080 size=1>KRUNOSLAV |
116 |
|
|
KOVACEVIC, Ph. D. Chem.<br> |
117 |
|
|
Research & Development, Deputy to |
118 |
|
|
Director<br> |
119 |
|
|
Phone: 3851/3781 105, 3781 027<br> |
120 |
|
|
Fax: 3851/3703 175<br> |
121 |
|
|
E-mail: <a |
122 |
|
|
href="mailto:kruno.kovacevic@pliva.hr">kruno.kovacevic@pliva.hr</a><br> |
123 |
|
|
</font> </td> |
124 |
|
|
</tr> |
125 |
|
|
</tbody> |
126 |
|
|
</table> |
127 |
|
|
</td> |
128 |
|
|
</tr> |
129 |
|
|
<tr> |
130 |
|
|
<td height="2"> |
131 |
|
|
<hr size="1" width="100%"> |
132 |
|
|
</td> |
133 |
|
|
</tr> |
134 |
|
|
<tr> |
135 |
|
|
<td> |
136 |
|
|
<table cellspacing=0 cellpadding=0 width=360 border=0> |
137 |
|
|
<tbody> |
138 |
|
|
<tr> |
139 |
|
|
<td width=70><img height=81 src="p/portret_kolega.gif" width=70 border=0></td> |
140 |
|
|
<td width=15></td> |
141 |
|
|
<td valign=top align=left width=275><br> |
142 |
|
|
<font face=Arial color=#000080 size=1>MARKO |
143 |
|
|
KOLEGA, M.D., Ph.M.<br> |
144 |
|
|
Research & Development, Deputy to |
145 |
|
|
Director (+ New Res. Institute Building)<br> |
146 |
|
|
Phone: 3851/3781 163, 3781 098<br> |
147 |
|
|
Fax: 3851/3703 175<br> |
148 |
|
|
GSM/Cell: 38598/289 283<br> |
149 |
|
|
E-mail: <a href="mailto:marko.kolega@pliva.hr">marko.kolega@pliva.hr</a><br> |
150 |
|
|
</font> </td> |
151 |
|
|
</tr> |
152 |
|
|
</tbody> |
153 |
|
|
</table> |
154 |
|
|
</td> |
155 |
|
|
</tr> |
156 |
|
|
</table> |